Efficacy and Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis
European Journal of Neurology · 2025
DOI: 10.1111/ene.70358 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Maria-Ioanna Stefanou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Pseudotumor Cerebri. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Repurposing glucagon‐like peptide‐1 (GLP‐1) and GIP/GLP‐1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects and reductions in cerebrospinal fluid secretion and intracranial pressure in vivo.
Methods
We evaluated the safety and efficacy of GLP‐1 RAs and GIP/GLP‐1 RAs in IIH. MEDLINE and Scopus databases were searched for randomized‐controlled trials (RCT), non‐randomized clinical trials, or registries in adults with IIH.
Results
Two clinical trials (one RCT and one non‐randomized case–control) and two registries, comprising 1550 IIH patients (768 receiving GLP‐1 or GIP/GLP‐1 RAs) were included. Compared with standard‐of‐care, GLP‐1 or GIP/GLP‐1 RAs were associated with a significantly lower risk of papilledema (RR: 0.25; 95% CI: 0.15–0.43; p < 0.01) and visual disturbances or blindness (RR: 0.41; 95% CI: 0.18–0.92; p = 0.03), and a near‐significant trend toward reduced headache risk (RR: 0.61; 95% CI: 0.34–1.07; p = 0.08). Additionally, GLP‐1 RAs significantly reduced monthly headache days at 3 months (MD = −3.64; 95% CI: −6.26 to −1.03; p < 0.01) and at the end of follow‐up (MD = −4.82; 95% CI: −8.80 to −0.85; p = 0.02). No association was detected between GLP‐1 RAs and body mass index. No serious adverse events or treatment discontinuations were reported; mild gastrointestinal adverse events and nausea occurred in 88% (95% CI: 0.46–1.00) of GLP‐1 RA‐treated patients.
Conclusions
GLP‐1 and dual GIP/GLP‐1 RAs are associated with a significantly lower risk of papilledema and visual disturbances or blindness and a lower headache risk compared with standard‐of‐care. Additionally, GLP‐1 RAs significantly reduce the monthly headache burden. Well‐designed RCTs are needed to robustly evaluate the effects of GLP‐1 and GIP/GLP‐1 RAs in IIH, which likely extend beyond their weight‐loss‐inducing properties. Trial Registration PROSPERO registration ID: CRD42025650082
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Neurology & Stroke, Eberhard-Karls University of Tübingen, Tübingen, Germany.
- Second Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Second Department of Internal Medicine, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Hertie Institute for Clinical Brain Research, Eberhard-Karls University of Tübingen, Tübingen, Germany.
- First Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Irini Chatziralli, Panagiota-Eleni Tsalouchidou, Georgios Tsivgoulis
Zitieren
APA
Stefanou, M. I., Chatziralli, I., Lambadiari, V., Mengel, A., Foska, A., Chondrogianni, M., Bakola, E., Tsalouchidou, P. E., Mitsikostas, D. D., Siasos, G., Ziemann, U., & Tsivgoulis, G. (2025). Efficacy and Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis. European Journal of Neurology. https://doi.org/10.1111/ene.70358
Vancouver
Stefanou MI, Chatziralli I, Lambadiari V, Mengel A, Foska A, Chondrogianni M, et al. Efficacy and Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis. European Journal of Neurology. 2025. doi:10.1111/ene.70358
BibTeX
@article{Stefanou2025,
author = {Stefanou, Maria-Ioanna and Chatziralli, Irini and Lambadiari, Vaia and Mengel, Annerose and Foska, Aikaterini and Chondrogianni, Maria and Bakola, Eleni and Tsalouchidou, Panagiota-Eleni and Mitsikostas, Dimos D and Siasos, Gerasimos and Ziemann, Ulf and Tsivgoulis, Georgios},
title = {Efficacy and Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70358}
}
EUVIMED